1.
Br J Cancer
; 102(1): 1-7, 2010 Jan 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19935796
RESUMO
Developing rational targeted cancer drugs requires the implementation of pharmacodynamic (PD), preferably non-invasive, biomarkers to aid response assessment and patient follow-up. Magnetic resonance spectroscopy (MRS) allows the non-invasive study of tumour metabolism. We describe the MRS-detectable PD biomarkers resulting from the action of targeted therapeutics, and discuss their biological significance and future translation into clinical use.
